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The real challenge in the development of a controlled drug delivery system is not
just to sustain the drug release but also to prolong the presence of the dosage form in the
stomach or the upper small intestine until all the drug is completely released in the desi-
red period of time (1–2). The residence of a drug delivery system in the upper part of the
gastrointestinal tract (GIT) can be accomplished by several drug delivery systems, such
as intragastric floating systems (3), swelling and expandable systems (4), bioadhesive
systems (5), modified shape systems (6), high density systems (7), delayed gastric emp-
tying systems (8) and low density super porous systems (9).
Domperidone is a synthetic benzimidazole compound that acts as a dopamine D2
receptor antagonist. Domperidone is also used as a prokinetic agent for treatment of up-
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The purpose of the present study was to develop an op-
timized gastric floating drug delivery system (GFDDS)
containing domperidone as a model drug. Box-Behnken
design was employed in formulating the GFDDS with
three polymers: hydroxypropyl methylcellulose K4M
(HPMC K4M) (X1), Carbopol 934P (X2) and sodium algi-
nate (X3), as independent variables. Floating lag time
(FLT), total floating time (TFT), time required to release
50% of the drug (t50) and diffusion exponent (n) were se-
lected as dependent variables. Seventeen formulations
were prepared, dissolution data obtained was fitted to
the power law and floating profiles were analyzed.
HPMC loading was found to be significant for floating
properties. Carbopol loading had a negative effect on
floating properties but was found helpful in controlling
the release rate of the drug. No significant effect of so-
dium alginate on floating properties was observed but it
was important for gel formation. The quadratic mathe-
matical model developed could be used to predict for-
mulations with desired release and floating properties.
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per gastrointestinal motility disorders (10). It continues to be an attractive alternative to
metoclopramide because it has fewer neurological side effects. Patients receiving dom-
peridone or other prokinetic agents for diabetic gastropathy or gastroparesis should be
also managing a diet, lifestyle, and other medications to optimize gastric motility (11).
After oral administration, domperidone is rapidly absorbed from the stomach and the
upper part of the GIT with fewer side effects (12–14). It is a weak base with good solubi-
lity in acidic pH but significantly reduced solubility in alkaline medium. Such a weak
base, formulated as an oral controlled release dosage form is exposed to environments
of increasing pH with subsequent precipitation of poorly soluble free base within the
formulation that is no longer capable of being released from the formulation (15).
The present study involved the design of domperidone gastric floating matrix tab-
lets by combining three polymers: HPMC K4M, Carbopol 934P and sodium alginate,
and investigation of the combined effect of these polymers on the floating behavior and
in vitro release pattern of the drug.
EXPERIMENTAL
Materials
Domperidone was obtained as a gift sample (Mann Pharmaceutical Ltd., India).
Hydroxypropyl methylcellulose K4M (HPMC K4M) and Carbopol 934P were received
as gift samples from the Torrent Research Center (India). Sodium alginate (SA), sodium
bicarbonate and lactose were purchased from S.D. Fine Chemicals (India).
Methods
Formulation design. – DESIGN EXPERT 6.0.11 (STAT-EASE) demo version software
was used for formulation design. The Box-Behnken design was used in the study. In this
design, three factors were evaluated and experimental trials were performed in all 17
possible combinations. The amounts of HPMC K4M (X1), Carbopol 934P (X2) and SA
(X3) were selected as independent variables. The floating lag time (FLT), total floating ti-
me (TFT) and times required for 50% of drug release (t50) and diffusion exponent (n) we-
re selected as dependent variables. The experimental design with the corresponding for-
mulations is outlined in Table I. The statistical model:
Y = b0+b1X1 + b2X2 + b3X3 + b11X1 X1 + b22X2 X2 + b12X1 X2 + b23X2X3 + b13X1X3 + E
incorporating interactive and polynomial terms was used to evaluate the responses,
where Y is the dependent variable, b0 is the mean response of 17 runs and bi is the esti-
mated coefficient for factor Xi. The main effects (X1, X2 and X3) represent the average re-
sult of changing 1 factor at a time from its low to high values. The interaction terms
(X1X2, X2X3 and X1X3) show how the response changes when 2 factors are simultaneous-
ly changed. The polynomial terms (X1X1, X2X2, and X3X3) are included to investigate
nonlinearity.
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Fabrication of domperidone floating tablets. – Domperidone was mixed with the requi-
red quantity of HPMC K4M, Carbopol 934P, SA, sodium bicarbonate and lactose with a
spatula in a mortar for 5 min. Isopropyl alcohol was added dropwise until a suitable
mass for granulation was obtained. Then the wet mass was granulated through a sieve
with 420 m aperture size. The granules were dried at room temperature (35 °C) for 1 h
and then blended with 5% polyethylene glycol 4000, 1% magnesium stearate and com-
pressed on a 10-station rotary tablet compression machine (Rimek, India) using a 8-mm
standard flat-face punch. The prepared tablets were round and flat with an average dia-
meter of 8.0  0.1 mm and a thickness of 2.8  0.2 mm.
In vitro buoyancy studies. – The in vitro buoyancy was determined by floating lag ti-
mes according to the method described by Rosa et al. (16). The tablets were placed in a
100-mL beaker containing 0.1 mol L–1 HCl. The time required for the tablet to rise to the
surface and float was taken as the floating lag time. The experiments were conducted in
triplicate.
In vitro dissolution studies. – The release rate of domperidone from floating matrix
tablets (n = 3) was determined according to British Pharmacopoeia (17) using the Disso-
lution Testing Apparatus 2 (paddle method). The dissolution test was performed using
900 mL of 0.1 mol L–1 HCl, at 37  0.5 °C and 50 rpm. A 5-mL sample was withdrawn
from the dissolution apparatus hourly for 12 h, and the samples were replaced with
fresh dissolution medium. The samples were filtered through a 0.45-m membrane filter
and diluted to a suitable concentration with 0.1 mol L–1 HCl. Absorbance of these solu-
tions was measured at 284 nm using a Shimadzu UV-1700 UV/Vis double-beam spec-
trophotometer (Japan). Cumulative drug release was calculated using the equation ge-
nerated from Beer Lambert’s calibration curve in the linearity range of 0–25 g mL–1.
FLT and TFT of the tablets were measured during dissolution studies. The t50 and n we-
re calculated based on the Korsmeyer and Peppas model (18).
Statistical analysis. – Statistical analysis of the Box-Behnken design batches was per-
formed by multiple regression analysis using Microsoft Excel. To evaluate the contribu-
tion of each factor with different levels to the response, the two-way analysis of variance
(ANOVA) was performed using the DESIGN EXPERT 6.0.11 (STAT-EASE) demo version
software. To graphically demonstrate the influence of each factor on the response, the re-
sponse surface plots were generated using the DESIGN EXPERT 6.0.11 (STAT-EASE) de-
mo version software.
RESULTS AND DISCUSSION
In the present investigation, combinations of three polymers were studied using the
Box Behken design. The mathematical models developed for all the dependent variables
using statistical analysis software are shown in Equations (1)–(4):
FLT = 8.41 + 0.63X1 – 2.13X2 + 3.25X3 + 3.51X1X2 + 2.75X1X3 +
+ 1.25X2X3 – 5.95X1X1 + 7.55X2X2 + 3.32X3X3
R = 0.599582 (1)
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TFT = 5.98 + 4.6875X1 – 3.2625X2 – 0.21X3 – 4.47X1X2 –
– 6.92X1X3 – 2.35X2X3 + 3.40X1X1 – 0.65X2X2 + 1.72X3X3
R = 0.898329 (2)
t50 = 14.84 – 0.14X1 – 0.28X2 + 1.21X3 – 0.45X1X2 + 1.08X1X3 –
– 0.05X2X3 + 1.7425X1X1 + 1.87X2X2 – 0.66X3X3
R = 0.928214 (3)
n = 0.38 + 0.02X1 – 0.01X2 + 0.02X3 – 0.01X1X2 – 0.03X1X3 –
– 0.01X2X3 – 0.07X1X1 + 0.02X2X2 – 0.04X3X3
R = 0.845881 (4)
The floating lag time for all tablets was found to be below 33 s regardless of the con-
tent of polymers used (Table I), indicating insignificant effect of the concentration of po-
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Table I. Formulation and dissolution characteristics (response data) of batches
in the Box-Behnken designa
Batch X1 (%) X2 (%) X3 (%) FLT (s) TFT (h) t50 (h) n
B1 10 15 25 2  1 2.5  0.4 13.1  0.0 0.48  0.02
B2 20 5 15 9  2 10.0  0.4 12.5  0.1 0.57  0.01
B3 30 5 25 4  2 24.0  0.3 13.3  0.0 0.52  0.03
B4 10 10 15 11  2 4.2  0.3 12.0  0.1 0.60  0.02
B5 10 10 35 5  2 5.3  0.3 11.9  0.0 0.65  0.07
B6 20 5 35 3  2 24.0  0.3 14.8  0.1 0.52  0.01
B7 30 10 35 26  4 5.6  0.4 14.7  0.1 0.51  0.01
B8 10 5 25 4  2 8.0  0.4 12.0  0.0 0.39  0.02
B9 20 10 25 3  2 2.5  0.2 15.8  0.0 0.44  0.01
B10 30 15 25 15  3 4.4  0.1 12.0  0.0 0.52  0.03
B11 20 15 15 33  4 3.6  0.3 12.8  0.0 0.62  0.02
B12 20 15 25 15  4 4.9  0.2 11.1  0.0 0.47  0.04
B13 30 10 15 3  1 24.0  0.4 11.3  0.1 0.36  0.06
B14 20 10 25 24  3 4.8  0.2 10.5  0.0 0.50  0.01
B15 20 10 25 10  2 6.8  0.5 15.0  0.1 0.48  0.04
B16 20 10 25 6  2 7.0  0.4 13.2  0.1 0.70  0.03
B17 20 10 25 12  2 4.2  0.3 13.2  0.0 0.45  0.02
a t50 – time requir ed to release 50% of drug, X1 – amount of HPMC K4M, X2 – amount of Carbopol 934P,
X3 – amount of sodium alginate.
All batches contain 30 mg of domperidone, 10% sodium bicarbonate, 5% polyethylene glycol, 1% magnesium
stearate, and a sufficient quantity of lactose to adjust the average mass of tablets to 180 mg.
lymers (Table II). Lower value of the correlation coefficient (Eq. 1) clearly indicates that
the response is independent of the factors studied. This was due to evolution and en-
trapment of carbon dioxide inside the hydrated polymeric matrices, resulting from the
interaction between the gas generating agent (NaHCO3) and dissolution medium (0.1
mol L–1 HCl, pH 1.2) which led to lowering of the density of matrices enabling the tab-
lets to float.
The results of TFT and t50 showed wide variations (Table I). From the results of mul-
tiple regression analysis, it was found that the dependent variables, TFT and t50, are
strongly dependent on the independent variables (p < 0.05, Table II). The correlation co-
efficients indicate a good fit. Polynomial equations (Eq. 2 and 3) can be used to draw a
conclusion after considering the magnitude of the coefficient and the mathematical sign
it carries (positive or negative). As the amount of Carbopol 934P increased, TFT decrea-
sed; this may be due to high affinity of Carbopol toward water, which promotes water
penetration into tablet matrices, leading to increased density. As the amount of HPMC
K4M increased, TFT increased; this is because of increased gel strength of matrices, which
prevents escape of evolved carbon dioxide from matrices, leading to decreased density.
As the amount of SA increased, TFT decreased; this is because of the poor gelling
strength of SA compared to HPMC K4M. This effect of polymer concentration is reflec-
ted in formulations B3, B6 and B13 (shown in Table I). As the amount of HPMC K4M
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Table II. Analysis of variance for dependent variables from the Box Behnken design
Source SS df MS F-value Probability
FLT
Regression 209.25 6 34.875 0.416031 0.8524
Residual 838.2794 10 83.82794
Total 1047.529 16
TFT
Regression 225.4207 9 25.04674 9.179194 0.0040
Residual 19.1005 7 2.728643
Total 244.5212 16
t50
Regression 47.83579 9 5.315088 10.05693 0.0030
Residual 3.6995 7 0.5285
Total 51.53529 16
n
Regression 0.03816 9 0.00424 1.418594 0.3297
Residual 0.020922 7 0.002989
Total 0.059081 16
SS – sum of squares
df – degrees of freedom
MS – mean of square
F – Fischer’s ratio
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Fig. 1. Response surface plot for the effect of polymer amount on a) floating lag time (FLT); b) total
floating time (TFT); c) time required for 50% drug release (t50); d) diffusion exponent (n). X1 –
amount of HPMC K4M, X2 – amount of Carbopol 934P; X3 – amount of sodium alginate.
and Carbopol 934P increased, t50 decreased; this may be due again to high affinity of
HPMC and Carbopol toward water, which promotes water penetration into tablet matri-
ces, leading to solubilization of domperidone. As the amount of SA increased, t50 decrea-
sed; probably because of poor water affinity of SA compared to HPMC K4M and Carbo-
pol 934P.
To demonstrate graphically the effect of the amount of HPMC K4M and Carbopol
934P and SA, the response surface plots were generated for the dependent variables FLT,
TFT, t50% and n (Fig. 1).
Dissolution profiles of the developed formulations are compared in Fig. 2. The dis-
solution profiles were fitted with the power law equation given by Korsmeyer and Pap-
pas (18). Although the type of polymer and its concentration had significant influence
on TFT and t50 (p < 0.05, Table II), the diffusion exponent ranged from 0.386 to 0.695, in-
dicating anomalous drug release involving a combination of swelling, diffusion and/or
erosion of matrices. This might be due to poor water solubility of domperidone as well
as different characteristics of polymers. Nonlinear relationship was obtained between
the diffusion exponent and three independent variables. It was observed that as the con-
centration of HPMC K4M increased, diffusion exponent increased up to an intermediate
value and decreased. Carbopol 934P concentration had no significant effect on the value
of n. As the concentration of SA increased, the values of n decreased.
CONCLUSIONS
HPMC K4M, Carbopol 934P and SA significantly affect TFT of the formulated
GFDDS. When they are used in combination for developing GFDDS, high to moderate
amount of HPMC K4M, low to moderate amount of Carbopol 934P and low to high
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Fig. 2. Comparative release pro-
file of developed formulations.
amount of SA is to be used to achieve the desired TFT and release profile required for
once daily formulations.
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S A @ E T A K
Plutaju}e matriks tablete: Dizajniranje i optimizacija kombiniranjem polimera
SHAILESH T. PRAJAPATI, LAXMANBHAI D. PATEL i DASHARATH M. PATEL
Cilj rada bio je razvoj i optimizacija plutaju}ih sustava za isporuku lijekova u `elucu
(GFDDS) s domperidonom kao modelom lijeka. Box-Behnkenovo dizajniranje kori{teno
je u formuliranju GFDDS. Nezavisne varijable u dizajniranju bila su tri polimera: hid-
roksipropil metilceluloza K4M (HPMC K4M) (X1), Carbopol 934P (X2) i natrijev alginat
(X3), a zavisne varijable usporeno vrijeme plutanja (FLT), ukupno vrijeme plutanja (TFT),
vrijeme potrebno za osloba|anje 50% lijeka (t50) i difuzijski eksponent (n). Pripravljeno
je ukupno sedamnaest formulacija. Analizirani su podaci o osloba|anju ljekovite tvari.
Koli~ina HPMC zna~ajno utje~e na svojstva plutanja, dok koli~ina karbopola ima nega-
tivni u~inak na svojstvo plutanja, ali kontrolira osloba|anje ljekovite tvari. Natrijev algi-
nat nema zna~ajni u~inak na svojstva plutanja, ali utje~e na stvaranje gela. Kvadratni
matemati~ki model mo`e se upotrijebiti za predvi|anje formulacija sa `eljenim profilom
osloba|anja i svojstvima plutanja.
Klju~ne rije~i: domperidon, plutaju}e matriks tablete, Box-Behnkenovo dizajniranje, GFDDS, kineti-
ka osloba|anja
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